Tasly Pharmaceutical Group Co., Ltd
Tasly Pharmaceutical Group Co., Ltd., commonly referred to as Tasly, is a leading player in the pharmaceutical industry, headquartered in China (CN). Founded in 1994, the company has established a strong presence in both domestic and international markets, with significant operations across Asia, Europe, and North America. Specialising in traditional Chinese medicine and modern pharmaceuticals, Tasly is renowned for its innovative products, including herbal remedies and cardiovascular treatments. The company’s commitment to research and development has led to numerous breakthroughs, positioning it as a pioneer in integrating traditional practices with contemporary science. With a robust market presence, Tasly has achieved notable milestones, including multiple certifications for its quality management systems. Its dedication to enhancing health and well-being through unique, effective solutions continues to solidify its reputation as a trusted name in the global healthcare landscape.
DitchCarbon Score
How does Tasly Pharmaceutical Group Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tasly Pharmaceutical Group Co., Ltd's score of 26 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tasly Pharmaceutical Group Co., Ltd's reported carbon emissions
In 2022, Tasly Pharmaceutical Group Co., Ltd reported total carbon emissions of approximately 5,570,430 kg CO2e. This figure includes 442,980 kg CO2e from Scope 1 emissions and 5,127,450 kg CO2e from Scope 2 emissions. The company has shown a significant increase in emissions compared to 2021, when total emissions were about 3,564,820 kg CO2e, with Scope 1 at 26,240 kg CO2e and Scope 2 at 3,538,580 kg CO2e. In 2020, the total emissions were approximately 2,092,050 kg CO2e, comprising 43,730 kg CO2e from Scope 1 and 2,048,320 kg CO2e from Scope 2. Despite the increase in emissions over the past two years, Tasly Pharmaceutical has not publicly disclosed any specific reduction targets or initiatives as part of its climate commitments. The company does not report Scope 3 emissions, which encompass indirect emissions in the value chain. Tasly Pharmaceutical's emissions data is not cascaded from any parent company, indicating that the reported figures are solely from its own operations. The company continues to monitor its carbon footprint and may consider future commitments to align with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 43,730 | 00,000 | 000,000 |
| Scope 2 | 2,048,320 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tasly Pharmaceutical Group Co., Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
